These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 416831)

  • 1. The reversible biotransformation of N-acetylprocainamide in the rhesus monkey.
    Ding TL; Lin ET; Benet LZ
    Arzneimittelforschung; 1978; 28(2):281-3. PubMed ID: 416831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of procainamide and N-acetylprocainamide in protein-calorie malnutrition.
    Jung D; Nanavaty M; Prasad P
    Drug Metab Dispos; 1985; 13(3):359-63. PubMed ID: 2410212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of N-acetylprocainamide from mixed diet in rats.
    Kamath BL; Yacobi A; Gupta SD; Stampfli H; Durrani M; Lai CM
    Res Commun Chem Pathol Pharmacol; 1981 May; 32(2):299-308. PubMed ID: 6166034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of diethylstilbestrol in the rhesus monkey and the chimpanzee.
    Metzler M; Müller W; Hobson WC
    J Toxicol Environ Health; 1977 Oct; 3(3):439-50. PubMed ID: 411947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog.
    Bagwell EE; Walle T; Drayer DE; Reidenbert MM; Pruett JK
    J Pharmacol Exp Ther; 1976 Apr; 197(1):38-48. PubMed ID: 1263131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quantitative disposition of procainamide and N-acetylprocainamide in the rat.
    Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH
    J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of N-acetylprocainamide.
    Atkinson AJ; Ruo TI
    Angiology; 1986 Dec; 37(12 Pt 2):959-67. PubMed ID: 2433970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of desethyl procainamide in patients: a new metabolite of procainamide.
    Ruo TI; Morita Y; Atkinson AJ; Henthorn T; Thenot JP
    J Pharmacol Exp Ther; 1981 Feb; 216(2):357-62. PubMed ID: 6162026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
    Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic potency of procainamide and N-acetylprocainamide in rabbits.
    Minchin RF; Ilett KF; Paterson JW
    Eur J Pharmacol; 1978 Jan; 47(1):51-6. PubMed ID: 618730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age, renal function and heart failure on procainamide clearance and n-acetylprocainamide serum concentrations.
    Bauer LA; Black D; Gensler A; Sprinkle J
    Int J Clin Pharmacol Ther Toxicol; 1989 May; 27(5):213-6. PubMed ID: 2472362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide.
    Atkinson AJ; Ruo TI; Piergies AA
    Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absolute bioavailability in man of N-acetylprocainamide determined by a novel stable isotope method.
    Strong JM; Dutcher JS; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):613-22. PubMed ID: 1183141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective plasma concentration of N-acetylprocainamide in rats.
    Yacobi A; Krasula RW; Lai CM; Kamath BL
    Res Commun Chem Pathol Pharmacol; 1979 Apr; 24(1):197-200. PubMed ID: 432435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inotropic actions of N-acetylprocainamide: blockade and reversal by propranolol.
    Lertora JJ; King LW; Donkor KA
    Angiology; 1986 Dec; 37(12 Pt 2):939-49. PubMed ID: 2433968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procainamide, N-acetylprocainamide, antinuclear antibody and systemic lupus erythematosus.
    Reidenberg MM; Drayer DE
    Angiology; 1986 Dec; 37(12 Pt 2):968-71. PubMed ID: 2433971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of procainamide and N-acetylprocainamide in rats.
    Kamath BL; Lai CM; Gupta SD; Durrani MJ; Yacobi A
    J Pharm Sci; 1981 Mar; 70(3):299-302. PubMed ID: 6167709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of coronary artery ligation on the pharmacokinetics of N-acetylprocainamide in dogs.
    Lai CM; Reynolds RD; Kamath BL; Calzadilla S; Gupta SD; Look ZM; Yacobi A
    Res Commun Chem Pathol Pharmacol; 1980 Aug; 29(2):369-72. PubMed ID: 6158076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.